Table 1 Characteristics of the whole cohort.
Global cohort | PV | ET | |
|---|---|---|---|
Participants (n) | 191 | 97 | 94 |
Age at diagnosis (y) | 65 [23; 90] | 64 [24; 90] | 65 [23; 85] |
Gender (M/F) | 96 (50.26%)/95 (49.74%) R: 1.01 | 56 (57.73%)/41 (42.27%) R: 1.37 | 40 (42.55%)/54 (57.45%) R: 0.74 |
At diagnosis | |||
Biological data at diagnosis (median [IQR]) | |||
Hemoglobin (g/dL) | 15.6 [11.2;25] | 17.8 [12.2;25] | 14.6 [11.2;17.7] |
Hematocrit (%) | 46.9 [33.5;72.8] | 53.6 [40.8;72.8] | 43.7 [33.5;52.7] |
Platelets (G/L) | 618 [135;1378] | 514 [135;1262] | 698 [392;1378] |
Leukocytes (G/L) | 9.8 [4.4;21.3] | 10.7 [5.5;21.3] | 8.95 [4.4;18] |
Neutrophils (G/L) | 6.9 [1.15;18.5] | 8 [1.15;18.5] | 6.2 [2.8;15.35] |
JAK2V617F allele burden (%) | 24.24 [1.26; 94.96] | 39.81 [1.26; 94.96] | 15.3 [1.66; 68.36] |
At 3 y FU | |||
Biological data at 3 y FU (median [IQR]) | |||
Hemoglobin (g/dL) | 13.9 [8.9; 17.9] | 14.1 [8.9; 17.9] | 13.7 [10.8; 17.3] |
Hematocrit (%) | 41.7 [29.8; 55.1] | 42.8 [29.8; 55.1] | 40.85 [32.2; 52.8] |
Platelets (G/L) | 350 [98; 1110] | 287 [98; 712] | 386.5 [149; 1110] |
Leucocytes (G/L) | 6.2 [2.2; 38.2] | 6.2 [2.6; 38.2] | 6.5 [2.2; 18.5] |
Neutrophils (G/L) | 4.3 [1.08; 16] | 4.2 [1.08; 16] | 4.45 [1.3; 15.8] |
JAK2V617F allele burden (%) | 15.02 [0; 91.37] | 24.37 [0.12; 91.37] | 10.075 [0; 80.25] |
Absolute change in allele burden | −5.1 [−81; +36.98] | −9.82 [−81; +36.98] | −2.125 [−31.7; +25.1] |
Relative change in allele burden | −21.088 [−100; +578.659] | −33.56 [−99.255; +578.659] | −16.2 [−100; +233.65] |
Decreased allele burden (absolute ≥−10% or relative ≥−50%) | 77 (40.3%) | 50 (51.5%) | 27 (28.7%) |
Recorded events at inclusion (n, %) | |||
Splenomegaly (clinical or volume >12 with ultrasound) | 52 (27.2%) | 36 (37.1%) | 16 (17%) |
Thrombosis history | 64 (33.5%) | 30 (30.9%) | 34 (36.2%) |
Hemorrhage history | 16 (8.4%) | 8 (8.3%) | 8 (8.5%) |
Worsening status at 3 y FU (n, %) | 58 (30.4%) | 31 (32%) | 27 (28.7%) |
1 event | 48 (82.8%) | 27 (87.1%) | 21 (77.8%) |
2 events | 8 (13.8%) | 4 (12.9%) | 4 (14.8%) |
3 events | 2 (3.4%) | 0 (0%) | 2 (7.4%) |
Long-term follow-up | |||
Follow-up time in years (median [IQR])) | 10.6 [3; 14.6] | 10.5 [3; 14.1] | 10.6 [3.3; 14.6] |
Thrombosis | 35 (18.3%) | 19 (19.6 %) | 16 (17. 0%) |
Transformation | 24 (12.6%) | 12 (12.4%) | 12 (12.8%) |
Including secondary MF | 14 (7.3%) | 6 (6.2%) | 8 (8.5%) |
Including secondary LAM | 10 (5.2%) | 6 (6.2%) | 4 (4.3%) |
Including secondary MDS | 2 (1%) | 1 (1%) | 1 (1.1%) |
Deaths | 51 (26.7%) | 31 (32%) | 20 (21.3%) |
